181 related articles for article (PubMed ID: 26923603)
1. P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer.
Goel HL; Pursell B; Shultz LD; Greiner DL; Brekken RA; Vander Kooi CW; Mercurio AM
Cell Rep; 2016 Mar; 14(9):2193-2208. PubMed ID: 26923603
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
[TBL] [Abstract][Full Text] [Related]
4. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
[TBL] [Abstract][Full Text] [Related]
5. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
[TBL] [Abstract][Full Text] [Related]
6. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
[TBL] [Abstract][Full Text] [Related]
8. VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells.
Tomida C; Yamagishi N; Nagano H; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
Int J Oncol; 2018 Apr; 52(4):1350-1362. PubMed ID: 29532881
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
[TBL] [Abstract][Full Text] [Related]
10. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
11. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
Voce P; D'Agostino M; Moretti S; Sponziello M; Rhoden K; Calcinaro F; Tamburrano G; Tallini G; Puxeddu E; Filetti S; Russo D; Durante C
Oncol Rep; 2011 Nov; 26(5):1075-80. PubMed ID: 21850379
[TBL] [Abstract][Full Text] [Related]
13. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Lucio-Eterovic AK; Piao Y; de Groot JF
Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
[TBL] [Abstract][Full Text] [Related]
14. VEGF-neuropilin-2 signaling promotes stem-like traits in breast cancer cells by TAZ-mediated repression of the Rac GAP β2-chimaerin.
Elaimy AL; Guru S; Chang C; Ou J; Amante JJ; Zhu LJ; Goel HL; Mercurio AM
Sci Signal; 2018 May; 11(528):. PubMed ID: 29717062
[TBL] [Abstract][Full Text] [Related]
15. TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer.
Deng Z; Zhou J; Han X; Li X
Oncol Rep; 2016 Jan; 35(1):359-65. PubMed ID: 26531153
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
17. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis.
Qin J; Xie Y; Wang B; Hoshino M; Wolff DW; Zhao J; Scofield MA; Dowd FJ; Lin MF; Tu Y
Oncogene; 2009 Apr; 28(16):1853-63. PubMed ID: 19305425
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
20. Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies.
Faes S; Uldry E; Planche A; Santoro T; Pythoud C; Demartines N; Dormond O
Oncotarget; 2016 Dec; 7(52):86026-86038. PubMed ID: 27852069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
